Monday, April 20, 2026 1:29:39 PM
Presenting thru 4-22, designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration.
If they can kill cancer and not healthy cells,specifically target and change after injection,and not cause immune system destruction ,it would be a first of a kind!
That ticker would be priceless with no top!
Greed should be high here if SNTI gets found,I see one person with 27k followers just posted buy SNTI
If they can kill cancer and not healthy cells,specifically target and change after injection,and not cause immune system destruction ,it would be a first of a kind!
That ticker would be priceless with no top!
Greed should be high here if SNTI gets found,I see one person with 27k followers just posted buy SNTI
Recent SNTI News
- Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase • GlobeNewswire Inc. • 05/14/2026 12:45:00 PM
- Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program • GlobeNewswire Inc. • 05/14/2026 12:40:00 PM
- Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/13/2026 01:00:00 PM
- Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies • GlobeNewswire Inc. • 04/01/2026 12:45:00 PM
- Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2026 12:00:00 PM
- Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference • GlobeNewswire Inc. • 03/23/2026 01:00:00 PM
- Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 02:05:00 PM
- Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/24/2026 02:15:00 PM
- Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development • GlobeNewswire Inc. • 02/20/2026 01:50:00 PM
- Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) • GlobeNewswire Inc. • 02/11/2026 01:35:00 PM
- Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 • GlobeNewswire Inc. • 02/03/2026 02:00:00 PM
- Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation • GlobeNewswire Inc. • 01/14/2026 02:15:00 PM
- Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 01:55:00 PM
- Senti Biosciences Announces New Employment Inducement Grants • GlobeNewswire Inc. • 12/18/2025 10:30:00 PM
- Senti Biosciences Shares Jump 29% After Strong Trial Results and FDA RMAT Status • IH Market News • 12/09/2025 02:54:49 PM
- Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 12/09/2025 12:00:00 PM
- Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile • GlobeNewswire Inc. • 12/09/2025 12:00:00 PM
- Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET • GlobeNewswire Inc. • 12/04/2025 01:45:00 PM
- Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December • GlobeNewswire Inc. • 11/13/2025 09:30:00 PM
- Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 • GlobeNewswire Inc. • 11/03/2025 02:05:00 PM
- Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 10/16/2025 01:05:00 PM
- Senti Bio to Present at BioJapan • GlobeNewswire Inc. • 10/06/2025 01:05:00 PM
- Senti Bio to Present at the MedInvest Biotech & Pharma Conference • GlobeNewswire Inc. • 09/18/2025 01:15:00 PM
- Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 01:05:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/02/2025 12:15:16 PM
